Stock Ticker

  • Loading stock data...

Ebola Fears: Drug And Suit Makers Up In The Market

Boston, MA 10/13/2014 (wallstreetpr) – The Ebola menace is slowly finding its way in the U.S. after a nurse who cared for an Ebola patient was also diagnosed with the virus. Companies developing cures for the diseases lead by Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been on an upward swing. Focus is also slowly shifting to companies developing protection apparel that is being used by practitioners to attend to the infected patients.

Lakeland shares have as a result of the Ebola cases in the U.S. recorded an upward swing especially after a Dallas county sheriff deputy was diagnosed with the illness. Lakeland Financial Corporation (NASDAQ:LAKE) currently makes the ChemMax 1 Hazmat suit that is used to provide protection against blood-borne pathogens like the ones in Ebola. The deputy had issued a quarantine order to the family of the deceased Thomas Eric Duncan although his symptoms are reported not to be consistent with that of the Ebola virus.

Duncan succumbed to the deadly virus despite being administered Chimerix Inc. (NASDAQ:CMRX) experimental drug Brincindofovir. His death consequently affected the company’s reputation in the space late last week, consequently going down. Tekmira seems to be having an upper hand in the space after its experimental drug TKM-Ebola saved the life of an American doctor who had contracted the disease while working in a clinic in Liberia.

 Shares of Alpha Pro Tech, Ltd. (NYSEMKT:APT), which makes surgical masks and infection control products surged to an all-time high last week after a nurse in Dallas was diagnosed with the virus.

Inovio Pharmaceuticals Inc. (NASDAQ:INO), NewLink Genetics Corp (NASDAQ:NLNK) and BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), which have Ebola drugs in the pipeline awaiting trials, have also continued to register an impressive rally in the market.

GlaxoSmithKline plc (ADR)(NYSE:GSK) has confirmed that it is scaling up production of its Ebola vaccine but did not expect to produce it in masses anytime soon because of financial constraints. The same picture has also been portrayed by Sarepta, which is currently complaining that financial constraints will considerably affect its mass production capabilities.

Ibio Inc. (NYSEMKT:IBIO) stock also continues to taste high margins in the market especially after reports emerged that it might partner Caliber Biotherapeutics to ramp up production for the experimental Ebola drug Zmapp. Produced by privately owned Mapp Biopharmaceuticals, Zmapp is viewed as the most advanced Ebola drug at the moment

Ibio Inc. (NYSEMKT: IBIO), GlaxoSmithKline plc (ADR) (NYSE:GSK), Inovio Pharmaceuticals Inc. (NASDAQ:INO), NewLink Genetics Corp (NASDAQ:NLNK), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Alpha Pro Tech, Ltd. (NYSEMKT:APT), Chimerix Inc. (NASDAQ:CMRX), Lakeland Financial Corporation (NASDAQ:LKFN) Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and Sarepta Therapeutics Inc. (NASDAQ:SRPT).

Published by Lisa Ray

Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.

Recent Stories

Sponsored Content

Sign Up To Get Our Latest Stocks Alerts